Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma

NEXT STORY
Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
PREV STORY
FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1 First-in-Human Trial of Umbralisib in The Lancet Oncology

Umbralisib is structurally distinct from other PI3K delta inhibitors with greater selectivity to PI3K ...

author_avatar
NASDAQ Market News

Town & Country Animal Hospital Celebrates 18th Anniversary

OCALA, Fla., June 21, 2015 (GLOBE NEWSWIRE) -- Town & Country Animal Hospital in ...

author_avatar
NASDAQ Market News

Helsinn Advanced Synthesis wins across all categories at the 2018 CMO Leadership Awards

Helsinn Advanced Synthesis wins across all categories at the 2018 CMO Leadership Awards For ...

author_avatar
NASDAQ Market News